COPPELL, Texas--(BUSINESS WIRE)--ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced top-line results from the Acute Phase of its pivotal Phase 3 ZS-003 trial of ZS-9, a novel, investigational treatment for hyperkalemia. Preliminary top-line analyses of the safety and efficacy results of the Acute Phase showed that the trial met its primary endpoint, demonstrating a rapid, statistically significant reduction in serum potassium (K+) over the initial 48 hours. These results confirm the positive results demonstrated in the Phase 2 trial (ZS-002), a multicenter, double-blind, placebo-controlled study, which also met its primary efficacy endpoint. The results of both of these clinical trials support the safety and efficacy of ZS-9 in treating hyperkalemia, regardless of underlying cause. The data were presented by Stephen R. Ash, M.D., of Indiana University Health Arnett, during the High-Impact Clinical Trials Oral Session at ASN’s Kidney Week 2013.
Help employers find you! Check out all the jobs and post your resume.
